Correlation between compartmental tenofovir concentrations and an ex vivo rectal biopsy model of tissue infectibility in the RMP-02/MTN-006 phase 1 study.

by Nicola Richardson-Harman, Craig W Hendrix, Namandjé N Bumpus, Christine Mauck, Ross D Cranston, Kuo Yang, Julie Elliott, Karen Tanner, Ian McGowan, Angela Kashuba, Peter A Anton
Published 2014-01-01

A multi-compartment single and multiple dose pharmacokinetic comparison of rectally applied tenofovir 1% gel and oral tenofovir disoproxil fumarate.

by Kuo-Hsiung Yang, Craig Hendrix, Namandje Bumpus, Julie Elliott, Karen Tanner, Christine Mauck, Ross Cranston, Ian McGowan, Nicola Richardson-Harman, Peter A Anton, Angela D M Kashuba
Published 2014-01-01

First phase 1 double-blind, placebo-controlled, randomized rectal microbicide trial using UC781 gel with a novel index of ex vivo efficacy.

by Peter A Anton, Terry Saunders, Julie Elliott, Elena Khanukhova, Robert Dennis, Amy Adler, Galen Cortina, Karen Tanner, John Boscardin, William G Cumberland, Ying Zhou, Ana Ventuneac, Alex Carballo-Diéguez, Lorna Rabe, Timothy McCormick, Henry Gabelnick, Christine Mauck, Ian McGowan
Published 2011-01-01

A Phase 1 Randomized, Open Label, Rectal Safety, Acceptability, Pharmacokinetic, and Pharmacodynamic Study of Three Formulations of Tenofovir 1% Gel (the CHARM-01 Study).

by Ian Mcgowan, Ross D Cranston, Kathryn Duffill, Aaron Siegel, Jarret C Engstrom, Alexyi Nikiforov, Cindy Jacobson, Khaja K Rehman, Julie Elliott, Elena Khanukhova, Kaleab Abebe, Christine Mauck, Hans M L Spiegel, Charlene S Dezzutti, Lisa C Rohan, Mark A Marzinke, Hiwot Hiruy, Craig W Hendrix, Nicola Richardson-Harman, Peter A Anton
Published 2015-01-01